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ABSTRACT 
Objective 
To investigate the relationship between tumour stage at diagnosis and selected components of primary and 
secondary care in the diagnostic interval for breast, colorectal, lung and ovarian cancers.  
Methods 
Observational study based on data from 6,162 newly diagnosed symptomatic cancer patients from Module 
4 of the International Cancer Benchmarking Partnership. We analysed the odds of advanced stage of cancer 
as a flexible function of the length of primary care interval (days from first presentation to referral) and 
secondary care interval (days from referral to diagnosis), respectively, using logistic regression with restricted 
cubic splines. 
Results 
The association between time intervals and stage was similar for each type of cancer. A statistically significant 
U-shaped association was seen between the secondary care interval and the diagnosis of advanced rather 
than localised cancer; odds decreasing from the first day onwards and increasing around three and a half 
months. A different pattern was seen for the primary care interval; flat trends for colorectal and lung cancers 
and a slightly curved association for ovarian cancer, although not statistically significant.  
Conclusion 
The results confirm previous findings that some cancers may progress even within the relatively short time 
frame of regulated diagnostic intervals. The study supports the current emphasis on expediting symptomatic 
diagnosis of cancer. 
 
Keywords: Early Detection of Cancer, Diagnosis, Time Factors, Delayed Diagnosis, Waiting Lists, Breast 
Neoplasms, Colorectal Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Primary Health Care, Bias. 
 
 
INTRODUCTION 
The waiting time from the first presentation of symptoms in primary care to cancer diagnosis, herein referred 
to as the diagnostic interval, is a major concern for patients, healthcare providers and the healthcare system. 
Delayed diagnosis at several different sites has been suggested to impact cancer survival.(Moller et al., 2015; 
Neal et al., 2015; S Walters et al., 2015) From the system and provider perspective, the length of the 
diagnostic interval is becoming a benchmark for the quality of cancer care. From the patient perspective, the 
diagnostic interval has been associated with increasing anxiety and fear of cancer progression during the 
waiting time.(Eskander et al., 2013; Oudhoff, Timmermans, Knol, Bijnen, & van der Wal, 2007; Ringbaek, 
Borgeskov, Lange, & Viskum, 1999) 
Despite limited high-quality evidence on waiting-time outcomes, many healthcare systems have developed 
recommendations on “acceptable” diagnostic intervals. The guidelines by the National Institute for Health 
and Care Excellence (NICE) in the England and Wales state that patients suspected of cancer must be assessed 
within two weeks after referral from primary care.(Emery & Vedsted, 2015) Similar benchmarks have been 
adopted elsewhere, e.g. the Cancer Care Ontario Standards, the Scottish Cancer Referral Guidelines, the 
Victorian Optimal Care Pathways, and the Cancer Patient Pathways across Scandinavia.(“Optimal Care 
Pathways - Cancer Council Victoria,” n.d.; Probst, Hussain, & Andersen, 2012; SIGN, 2003; Wilkens, Thulesius, 
Schmidt, & Carlsson, 2016) 
Although the benefits of expedited diagnosis of symptomatic cancer cannot be experimentally tested, some 
evidence exists from observational studies. These have reported increasing mortality and advanced stage of 
disease with longer diagnostic intervals for breast cancer,(Ermiah et al., 2012; A R Jensen, Madsen, & 
Overgaard, 2008; Richards, Westcombe, Love, Littlejohns, & Ramirez, 1999; Warner et al., 2012) colorectal 
cancer,(Corley et al., 2017; Tørring et al., 2011; Tørring, Frydenberg, Hansen, Olesen, & Vedsted, 2012) head 
and neck cancers,(Chen, King, Pearcey, Kerba, & Mackillop, 2008; Liang et al., 2017; Murphy et al., 2016) 
endometrical cancer,(Dolly et al., 2016) and lung cancer.(Anni R Jensen, Mainz, & Overgaard, 2002; Olsson, 
Schultz, & Gould, 2009; Wang, Mahasittiwat, Wong, Quint, & Kong, 2012) Nevertheless, most of these 
findings need to be replicated using analytical methods that address many of the problems associated with 
previous studies of this nature.(Neal et al., 2015)  
The International Cancer Benchmarking Partnership (ICBP) is a major international collaboration aimed at 
exploring differences in cancer outcomes between countries with comparable wealth, access to universal 
healthcare and high-quality cancer registration.(Sarah Walters et al., 2013) The ICBP Module 4 (ICBP-M4) 
study was set up to describe cancer pathways and investigate the association between the diagnostic interval 
and outcomes of breast, colorectal, lung and ovarian cancers.(David Weller et al., 2016)  
The aim of this study was to investigate the relationship between tumour stage at diagnosis and selected 
components of primary and secondary care in the diagnostic interval for breast, colorectal, lung and ovarian 
cancers. To address confounding by indication, which could explain previous equivocal findings, we analysed 
stage of cancer as a flexible function of the length of time under primary and secondary care, respectively. 
 
METHODS 
We conducted a cohort study and calculated the odds of finding advanced stage cancer as the primary 
outcome while using the length of the diagnostic interval (defined as the time from the first presentation of 
symptoms in primary care to the date of diagnosis) as the exposure variable.  
Setting and population 
The ICBP-M4 study included all patients with newly diagnosed breast, colorectal, lung or ovarian cancers 
from cancer registries and hospital registries in 10 jurisdictions across the UK (Wales, England, Scotland, 
Northern Ireland), Scandinavia (Denmark, Sweden, Norway), Canada (Ontario, Manitoba) and Australia 
(Victoria) during 2013-2015. Patients below the age of 40 years with a prior history of cancer in the same 
site, or two or more primary cancers, were excluded. In the present study, patients from Sweden and Norway 
were ineligible due to lack of information on date of referral in the Swedish data and low participation in the 
Norwegian survey. 
Data collection 
Local ICBP-M4 teams sent a questionnaire to eligible patients, their primary care physician (PCP) and the 
main cancer treatment specialist (CTS), who provided a detailed description of the route to diagnosis, 
milestone dates, cancer-specific symptoms (yes/no), chronic morbidity, types of clinical investigations and 
tumour stage. In addition, the teams obtained information on date of diagnosis and tumour stage from 
cancer registries and clinical databases. Using registry data, we subsequently excluded patients with screen-
detected (i.e. non-symptomatic) cancer and patients with missing information on gender, age, date of 
consent and diagnosis. To avoid recall bias, we also excluded patients who completed the questionnaire more 
than nine months after diagnosis. In Manitoba, data on specialists were not collected. In Northern Ireland 
and Denmark, data on specialists were collected solely from clinical databases and registries. Data collection 
and data management has been described in further detail elsewhere.(David Weller et al., 2016) 
Defining exposures, outcome and covariates 
Dates encompassing the diagnostic interval were defined in line with the Aarhus Statement as the date of 
first presentation to a health professional and the date of diagnosis.(D Weller et al., 2012) We prioritised 
PCP-reported over patient-reported date of first presentation, as this date is known to be more 
reliable.(Larsen, Hansen, Sokolowski, & Vedsted, 2014) Date of referral was only provided by PCPs. We 
prioritised registry-recorded date of diagnosis over survey reports and defined diagnosis as histological 
confirmation of the malignancy. We defined and calculated three exposure variables as illustrated in Figure 
1: (a) the primary care interval (days from first presentation to referral to a CTS); (b) the secondary care 
interval (days from referral to diagnosis); and (c) the diagnostic interval (days from first presentation to 
diagnosis). All corresponding dates were validated manually in case of inconsistencies, and negative intervals 
were set to zero days. All intervals were truncated at 365 days. Outlier and missing dates were imputed based 
on specific rules to ensure that the direction of a possible misclassification bias was known (Supplementary 
material, Appendix I). 
The primary outcome of the study was tumour stage classified as stage I, II, III or IV according to the TNM 
staging system or according to the Dukes’ or FIGO staging system for colorectal cancer and ovarian cancer, 
respectively (see Appendix II). We ranked registry-based over CTS-reported staging and re-categorised the 
identified cases into a binary variable of advanced (stage III+IV) vs. localised (stage I+II) cancer (Appendix II). 
We obtained information on age and gender and patient-reported comorbidity defined as suffering from 
either heart disease, stroke, lung disease and/or diabetes (none=0; medium=1-2; high=3-4). Age was 
modelled as a categorical variable with three categories based on tertiles for each cancer type. 
Statistical analysis 
We analysed each cancer separately and modelled the data in two ways. First, we treated the care interval 
as a continuous variable using restricted cubic splines to make efficient use of within-category 
information.(Durrleman & Simon, 1989; Greenland, 1995) We used three knots according to Harrell’s 
recommended percentiles (Harrels, 2001) and chose an a priori reference of 30 days. We used logistic 
regression to estimate the odds ratio (OR) of being diagnosed with an advanced vs. localised cancer as a 
function of length of each diagnostic interval. Second, to confirm spline trends by a categorical analysis, we 
grouped intervals by allocating patients roughly based on their cancer and interval-specific percentiles 
(‘short’: below 0.75; ‘medium’: between 0.75 and 0.90; ‘long’: above 0.90) and calculated the adjusted OR 
for short or long vs. medium length of diagnostic intervals. In both models, we adjusted for age, gender, 
comorbidity and jurisdiction to allow for between-jurisdiction variability. Several sensitivity and agreement 
analyses tested the robustness of the models (Appendix VI).  
We calculated 95% confidence intervals (CIs) for all estimates and tested each model against a model with 
no diagnostic interval term using the likelihood-ratio test. A two-sided P-value of 0.05 or less was defined as 
statistically significant. Statistical analyses were carried out using Stata statistical software (version 14).  
 Patient and public involvement 
The research questions for the survey, which this study is based, drew on an extensive literature relating to 
diagnosis and treatment delays leading to negative patient experiences. Patients were involved in the piloting 
of study instruments to ascertain if recruitment and questionnaire content and dissemination strategies were 
appropriate, described elsewhere(David Weller et al., 2016).  
 
RESULTS 
The flow of patient identification, responses and exclusion is outlined in Figure 2. The flow for each type of 
cancer is shown in the supplementary material (Appendix III: Figures A1-A4). A total of 6,162 patients fulfilled 
the inclusion criteria. Of these, 2,544 patients (41%) were excluded due to missing time intervals. Finally, 
3,618 (59%) patient questionnaires were included in the analyses. Additionally, 3,618 (59%) PCP 
questionnaires and 1,974 (32%) CTS questionnaires were included. 
Patient description 
Patients with breast cancer were generally younger, suffered from less comorbidity, experienced much 
shorter diagnostic intervals (58% had no primary care delay) and were diagnosed with earlier tumour stages 
compared to patients with colorectal, lung and ovarian cancer. Ovarian cancer patients had the longest 
secondary care interval and were more likely to be diagnosed with an advanced cancer than patients with 
other types of cancer. Lung cancer patients had more comorbidity and generally experienced longer primary 
care intervals than patients with other types of cancer (Table 1). The clinical features were similar for each 
jurisdiction, except for the proportion diagnosed with advanced cancer, which tended to be highest in 
Northern Ireland and Denmark and lowest in Victoria and Canada depending on cancer site (Appendix IV: 
Table A1). 
Diagnostic interval and cancer stage 
The association between both primary and secondary care intervals and staging was similar for each type of 
cancer, but we observed opposite trends for the two intervals. For the primary care interval, we generally 
saw a flat trend, but a slightly concave or n-shaped association was seen for ovarian cancer with increasing 
and subsequently decreasing odds of advanced cancer with longer primary care intervals. However, these 
associations were not statistically significant (Figure 3, Table 2 and Appendix V: Figure A5-A7). For the 
secondary care interval, we observed a convex or U-shaped association with decreasing and subsequently 
increasing odds of advanced cancer with longer secondary care intervals. The U-shaped association was 
statistically significant for colorectal cancer (P=0.005), lung cancer (P<0.001) and ovarian cancer (P<0.001) 
and tended to be statistically significant for breast cancer (p=0.071). The crude curve estimates were similar 
to the adjusted estimates (Appendix V: Figure A8-A11).  
The pointwise estimates showed that the adjusted odds of being diagnosed with an advanced stage 
colorectal cancer decreased from the first day until the bottom point of 104 days, where it was around 27% 
lower than the odds for patients who waited 30 days from referral to diagnosis (OR=0.73; 95% CI: 0.59-0.89) 
(Figure 4 and Appendix V: Figure A8-A11). For breast cancer, the bottom point corresponded to 31 days 
(OR=1.00; 95% CI: 0.99-1.00); for lung cancer to 93 days (OR=0.52; 95% CI: 0.42-0.64); and for ovarian cancer 
to 104 days (OR=0.56; 95% CI: 0.43-0.76). The observed trends of the spline regression were confirmed by 
categorical analyses comparing short or long vs. medium secondary care intervals (Table 2). 
More equivocal trends were noted across the individual cancers for the diagnostic interval, and the 
associations were not statistically significant for lung and ovarian cancer (Appendix V: Figure A12).  
Our sensitivity analyses (Appendix VI) overall displayed similar findings as the main analysis, except when we 
included only PCP data as this decreased the U-shaped trend seen in the secondary care interval for breast 
and ovarian cancers.  
 
 
DISCUSSION 
While we found statistically significant associations between the length of time interval and cancer stage for 
all four types of cancer, the observed U-shaped trends only pertained to the secondary care component of 
the diagnostic interval. The trends for the primary care component were either flat or slightly n-shaped, but 
these were not statistically significant. 
Strengths of the study 
A main strength of the present population-based cohort study of 3,618 patients with incident colorectal, 
lung, breast or ovarian cancer is that selection and information bias was reduced owing to the use of highly 
reliable cancer registries with histological data on diagnoses and staging. The ICBP-M4 survey drew on state-
of-the-art instruments and went through extensive cognitive testing, piloting, translation and adaptation to 
ensure a high-quality, standardised and clinically validated dataset on diagnostic routes.(David Weller et al., 
2016) Additionally, we used benchmarked registries and approaches to produce comparable stage 
information.(Benitez-Majano, Fowler, Maringe, Di Girolamo, & Rachet, 2016; Deleuran et al., 2012; Ording 
et al., 2012; Ostenfeld et al., 2012; Tucker C, Howe L, & Weir K, 1999; Sarah Walters et al., 2013) By excluding 
screen-detected patients, we ensured a highly homogeneous group with respect to confounders and 
obtained better internal validity and relevance for all healthcare systems with a gatekeeper function. 
Furthermore, a main analytical strength of the study is that it addressed confounding by indication by making 
interval-specific models and by using restricted cubic splines, which allowed for a flexible relationship 
between exposure and outcome. 
Limitations of the study 
A number of limitations exist due to the cross-sectional study design, which does not permit direct inference 
of causality. This may also hold a risk of selection and information bias and of residual confounding. 
Firstly, the recruitment process in the ICBP-M4 required the patient to be alive for at least 3-4 months after 
diagnosis and for some up to 6 months after diagnosis.(David Weller et al., 2016) Bias is conceivable due to 
the exclusion of more advanced cases in some jurisdictions, which is likely to reflect patients who died during 
admission or treatment. This problem was perhaps most apparent for the jurisdiction of Victoria, which only 
included patients with less advanced stages of lung cancer who could be treated by surgery. The main effect 
of such information bias would be increased variation and fewer cases with short intervals and advanced 
stages; this would most likely have biased the results towards no association between time and stage. Hence, 
our estimates may have underestimated the true association. 
Secondly, 41% (2,544) of the study population could not be included in the final analyses due to missing 
information on time intervals; this was primarily due to missing PCP-reported date of referral. Compared to 
the 3,618 included, excluded study subjects had more early stage cancer and less comorbidity, but, 
differences were so small they can hardly have influenced the overall results (Appendix IV, Table A2). 
The length of the diagnostic interval may be subject to differential misclassification; this could be due to e.g. 
non-random recalling of dates when symptoms are vague, which is often the case for colorectal, lung and 
ovarian cancers.(Lyratzopoulos, Neal, Barbiere, Rubin, & Abel, 2012; Lyratzopoulos, Wardle, & Rubin, 2014) 
Furthermore, missing information is likely to confound all studies on staging and may have biased results if 
the quality of staging was associated with drop-out and/or diagnostic timeliness. Given the observed U-
shaped and n-shaped trends, it is difficult to predict the direction of potential selection and information bias. 
However, we compared the dates of first presentation to primary care between PCP and patient, and we also 
compared the date of diagnosis between all data sources available. These comparisons showed adequate 
agreement (CCC=0.92 and CCC≥0.95, respectively), which indicates that the bias raised is very limited. 
Unmeasured confounding by factors such as tumour grade/aggressiveness and socioeconomic status 
(including ethnicity and education), which were not universally available, may have influenced the results. 
We reduced this risk by adjusting for comorbidity and age, but residual confounding may still have resulted 
from imperfect adjustment and misclassification of other diseases. We observed no major changes in the 
estimates when controlling for measured comorbidity and age, and this speaks against the presence of 
residual confounding.  
Despite differences in data sources and construction, the clinical features of the patients were remarkably 
similar across cancer types and the eight jurisdictions. We obtained strikingly similar results, which suggests 
that selection and information bias cannot explain the observed trends.  
Finally, although stratification procedure, spline regression and interval-specific models were used to limit 
the risk of confounding and selection bias, this approach also reduced the statistical precision of the study. A 
larger study is needed to assess the cancer- and jurisdiction-specific effects. 
Comparison with findings from other studies 
Previous studies have reported that the so-called waiting-time paradox shows poor outcomes for patients 
with very short diagnostic intervals for various types of cancer.(Neal et al., 2015) Maguire and colleagues 
explicitly warned that failure to consider a non-linear effect may partly explain previous inconclusive 
findings.(Maguire et al., 1994) Our results confirm previous findings of a non-monotonic relationship (i.e. not 
constantly increasing (or decreasing) association) between the length of time intervals and mortality or 
staging for breast, colorectal, lung, skin, prostate and ovarian cancers.(Murchie et al., 2014; Redaniel, Martin, 
Cawthorn, Wade, & Jeffreys, 2013; Tørring et al., 2013) The authors analysed the staging of colorectal cancer 
as a function of the length of time under PCP care and specialist care, respectively, and found an n-shaped 
and a U-shaped association. This study confirms these findings for other types of cancers, jurisdictions and 
data sources and thus consolidates two important points made by Crawford et al. and Afzelius et al. several 
years ago; the basis for assignment of waiting time (the sorting of patients) changes during the diagnostic 
pathway, and the interval-specific models are necessary to achieve valid comparisons.(Afzelius, Zedeler, 
Sommer, Mouridsen, & Blichert-Toft, 1994; Crawford et al., 2002; Tørring et al., 2017)  
Underlying mechanisms  
We believe that the finding of the waiting-time paradox reflects confounding by indication; a bias stemming 
from the inherent difference in the prognosis of patients given different medical priority (i.e. the very sick 
patients are prioritised, but due to their advanced disease they are more prone to succumb). The diverse 
trends for both primary care intervals and secondary care intervals support the assumption that symptomatic 
cancer patients are classified and diagnosed at different pace, which is based on their gradually changing 
clinical indications and on the diagnostic tools available in primary and secondary care.  
The observed decreasing odds with longer secondary care intervals correspond well with a clinical reality in 
which patients are offered specialist care after primary care triage; this increases the probability of finding 
advanced stage tumours among expedited patients. Furthermore, in secondary care, the greater clinical 
experience of patients with cancer and ready access to hospital-based investigations ensure that patients 
with advanced disease who attend a specialist service are diagnosed very quickly, whereas patients with less 
clear symptoms and less advanced disease progression are managed less urgently. Hence, negative bias 
(where the observed effect is lower than the true value) is likely to explain the decreasing odds of advanced 
cancer with time. As a final tentative point, we propose that the observation of increasing odds of advanced 
cancer with secondary care intervals longer than approximately three and a half month could reflect the 
effect of false-negative tests or unnecessary delays in the investigation and/or treatment. Thus, health 
systems should focus on the effectiveness of the pathways after referral of patients from primary care. 
As with previous studies, we found no statistically significant association between the primary care interval 
and cancer stage. This is presumably due to potential bias from selection, information and confounding as 
well as confounding by indication inherited from the study designs, which are likely to have caused negative 
bias. Still, this does not indicate that time does not matter in primary care. It merely indicates the complex 
clinical and organisational process of selecting patients for referral to specialised investigation for cancer. 
The equivocal findings for the diagnostic interval and disease stage (Appendix V: Figure A12) underscore the 
central argument of the study: When we mix the waiting times for primary care and secondary care  (Hansen 
et al., 2011; Helsper, van Erp, Peeters, & de Wit, 2017; Swann et al., 2018), we do not only fail to acknowledge 
the complex and differential processes that shape the duration of primary care and secondary care; we also 
make the study vulnerable to type two errors and may even fail to reject a null hypothesis that is actually 
false. 
Clinical implications 
Our consistent findings of U-shaped associations are likely evidence of advanced stage cancer with longer 
diagnostic intervals. In many previous studies, the authors have seemed unprepared for meeting 
contradictory results. Instead of questioning their study design, many have ignored statistically significant 
reverse effects and claimed that the time duration of both diagnostic and treatment processes is too short 
to have any clinical relevance.(Brasme et al., 2012; Flemming et al., 2017; Iversen, Antonsen, Laurberg, & 
Lautrup, 2009; Nagle et al., 2011; Polissar, Sim, & Francis, 1981; Porta, Gallen, Malats, & Planas, 1991; 
Rupassara, Ponnusamy, Withanage, & Milewski, 2006; Sainsbury, Johnston, & Haward, 1999) We believe 
such conclusions to be erroneous, because clinical triage will inherently result in selecting the very ill patients 
to be prioritised. Even if most patients will experience necessary and/or unavoidable waiting time during 
their diagnostic interval, no ’safe’ amount of delay can be defined, at least not by an observational study. The 
inclusion of data from eight different jurisdictions across the globe emphasises the universal implications of 
these findings.  
Thus, the present study substantiates that observational studies are not ideal for testing whether waiting 
time matters or not on the patient's prognosis. It shows that wrong conclusions will be drawn from studies 
applying a simple linear or dichotomous model. On the backdrop of this, future studies should at least 
account for the inherent risk of different referral practices (such as fast-tracking more seriously ill patients) 
and strong confounders such as heterogeneity of the patient population, the heterogeneity of tumours and 
the rate of progression of the tumour.  
 
CONCLUSION 
We found that the waiting-time paradox is seen across different types of cancer, and we confirmed that the 
U-shaped association between waiting time and tumour stage is uniquely related to the secondary care 
component of the diagnostic interval. The study provides evidence that longer care intervals are associated 
with more advanced cancer staging; this is seen even in highly regulated universal healthcare systems with 
diagnostic guidelines and standardised procedures, including fast-track referrals. The study thereby supports 
efforts to shorten the clinical pathway.   
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Tables and table legends 
Table 1: Clinical features for symptomatic patients aged 40 YEARS or over with the first diagnosis of cancer 
displayed for each cancer (n (%) if nothing else IS stated) 
  
Breast cancer CRC Lung cancer 
Ovarian 
cancer 
Total 
(N=1058) (N=1069) (N=890) (N=601) (N=3618) 
Age (years), Median (IQI) 61 (50,73) 70 (61,78) 69 (64,75) 64 (56,72) 67 (58,75) 
Gender, Male, among CRC and Lung cancer 
patients 
 - 611 (57) 470 (53)  - 1,082 (55) 
Comorbidity1           
None 729 (69) 577 (54) 357 (40) 421 (70) 2,038 (58) 
Medium 314 (30) 463 (43) 485 (54) 175 (29) 1,437 (40) 
High 10 (1) 27 (3) 48 (5) 5 (1) 90 (2) 
Missing  5 (1) 2 (1) 0 (0) 0 (0) 7 (1) 
Tumour stage2           
I 353 (33) 179 (17) 218 (24) 165 (27) 914 (25) 
II 489 (46) 349 (33) 138 (16) 52 (9) 1,028 (28) 
III 135 (13) 357 (33) 249 (28) 261 (43) 1,002 (28) 
IV 35 (3) 146 (14) 248 (28) 82 (14) 511 (14) 
Missing 46 (4) 38 (4) 37 (4) 41 (7) 163 (5) 
Time interval, Median (IQI) days           
Primary care interval 0 (0,7) 2 (0,21) 14 (3,42) 7 (0,24) 4 (0,22) 
Secondary care interval 13 (6,21) 29 (14,70) 27 (13,59) 35 (14,62) 21 (10,51) 
Diagnostic interval 16 (9,30) 44 (21,97) 50  (26,108) 48 (26,97) 35 (15,79) 
1Comorbidity coded as none=none reported, medium=1-2 reported and high=3+ reported; IQI: inter-quartile interval 
2 TNM classification for breast and lung cancers, TNM or Duke’s classification for CRC, TNM or FIGO classification for ovarian cancer 
 
  
Table 2: Estimated odds ratios for tumour stage III-IV vs. I-II as a function of secondary- and primary care 
intervals, adjusted for jurisdiction, age, comorbidity and gender (Lung, CRC). The time intervals were treated 
as categorical variables. 
Time interval Cancer Time interval categories, 
days 
N Advanced stage 
% 
Crude OR 
(95% CI) 
Adjusted OR  
(95% CI) 
Primary Care Breast 0-15 836 16 0.82 (0.46-1.45) 0.63 (0.33-1.19) 
  16-30 84 19 1 (ref.) 1 (ref.) 
  >30 92 21 1.11 (0.53-2.32) 1.04 (0.49-2.22) 
       
 CRC 0-30 829 48 0.92 (0.62-1.37) 0.93 (0.62-1.39) 
  31-90 110 50 1 (ref.) 1 (ref.) 
  >90 92 54 1.19 (0.68-2.07) 1.11 (0.63-1.97) 
       
 Lung 0-30 568 61 1.36 (0.99-1.89) 1.29 (0.91-1.83) 
  31-90 200 54 1 (ref.) 1 (ref.) 
  >90 85 51 0.89 (0.54-1.48) 0.96 (0.56-1.65) 
       
 Ovarian 0-30 444 60 0.69 (0.40-1.19) 0.60 (0.34-1.07) 
  31-90 67 69 1 (ref.) 1 (ref.) 
  >90 49 61 0.72 (0.33-1.56) 0.65 (0.29-1.47) 
       
Secondary Care Breast 0-15 628 18 1.25 (0.87-1.81) 1.27 (0.86-1.89) 
  16-60 329 15 1 (ref.) 1 (ref.) 
  60 55 15 0.97 (0.43-2.18) 1.08 (0.47-2.47) 
       
 CRC 0-60 727 51 1.52 (1.08-2.13) 1.71 (1.20-2.44) 
  61-120 171 41 1 (ref.) 1 (ref.) 
  >120 133 45 1.19 (0.75-1.87) 1.20 (0.75-1.92) 
       
 Lung 0-60 644 63 2.49 (1.67-3.70) 2.14 (1.40-3.28) 
  61-120 121 41 1 (ref.) 1 (ref.) 
  >120 88 49 1.40 (0.81-2.44) 1.35 (0.75-2.44) 
       
 Ovarian 0-60 415 63 1.55 (0.99-2.41) 1.65 (1.03-2.64) 
  61-120 99 53 1 (ref.) 1 (ref.) 
  >120 46 63 1.54 (0.75-3.16) 1.33 (0.63-2.82) 
Bold numbers indicate statistically significant result at p<0.05 or less. 
  
FIGURE LEGENDS 
Figure 1: Definition of exposure variables. The three exposure variables based on date of first presentation 
of symptoms in primary care (B); date of referral to a cancer specialist centre (C); and date of diagnosis (D): 
“The primary care interval” as B-C = time from first presentation to referral to a cancer specialist centre, “The 
secondary care interval” as C-D = time from referral to diagnosis and “The diagnostic interval” as B-D = time 
from first presentation to diagnosis. 
 
Figure 2: Flowchart of patient inclusion. Boxes on the left indicate exclusion of patients, while boxes on the 
right indicate drop-outs. 
 
 
Figure 3: The odds of being diagnosed with advanced cancer as a function of primary care interval (time from 
presentation to referral). Estimated odds ratios of being diagnosed with advanced (stage III+IV) vs. localised 
(stage I+II) cancer as a function of the length of the primary care interval analysed for each type of cancer. 
We adjusted for age, gender (for lung and colorectal cancer), comorbidity and jurisdiction. The horizontal 
line indicates the chosen reference point of 30 days (see logistic regression details in Appendix V). 
Comparisons within breast cancer patients were not justified because more than half experienced no primary 
care delay. 
 
Figure 4: The risk of being diagnosed with advanced cancer as a function of secondary care interval (time 
from referral to diagnosis). Estimated odds ratios of being diagnosed with advanced (stage III+IV) vs. localised 
(stage I+II) cancer as a function of the length of the secondary care interval analysed for each type of cancer. 
We adjusted for age, gender (for lung and colorectal cancer), comorbidity and jurisdiction. The horizontal 
line indicates the chosen reference point of 30 days (see logistic regression details in Appendix V).  
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